Cytek Biosciences (CTKB) Goldman Sachs 45th Annual Global Healthcare Conference summary

Market performance and growth

• Organic growth rebounded from 1% in Q4 2023 to 11% in Q1 2024, driven by both services and instruments.

• Revenue growth target for 2024 is 5%-10%, with a focus on net income profitability and positive cash flow.

• Share repurchase program of $50 million was reinitiated, funded by operational cash flow.

• Strong performance in China and Europe, with China benefiting from leadership in full spectrum technology and Europe seeing a return to normal order patterns.

• U.S. and APAC (ex-China) sales cycles remain elongated, but forecasts account for this.

Technology and product strategy

• Full spectrum flow cytometry is now the industry standard, with Cytek pioneering this shift since 2017.

• Both analyzer and sorter technologies are available, supporting advanced cell analysis and sorting.

• Cloud-based bioinformatics platform launched 18 months ago, now with over 10,000 users, enhancing customer engagement and research efficiency.

• Reagent business is growing faster than instruments, though still a small revenue base; focus is on unique reagents for proprietary technology.

Operational and regional updates

• Manufacturing footprint expanded with a new 50,000 sq ft facility in Wuxi, China, supporting both local and global operations.

• Clinical tools are approved in China and Europe, with new clinical panels recently approved in China.

• Luminex acquisition improved service gross margins to over 50% and strengthened the commercial team, especially in Europe.